摘要
目的探讨二甲双胍联合瑞格列奈治疗2型糖尿病的临床效果及安全性，为2型糖尿病药物选择提供科学依据。方法选择2012年1月～2013年1月来本院内分泌科就诊的200例2型糖尿病患者，随机分为治疗组和对照组各100例，其中治疗组给予二甲双胍联合瑞格列奈治疗，对照组只给予二甲双胍治疗。结果两组患者治疗前餐后2h血糖（2hPG）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）水平差异均无统计学意义（P〉0．05），治疗后8周治疗组患者2hPG、FBG、HbA1c水平均明显低于对照组（P〈0．05），两组低血糖、恶心、呕吐、腹泻发生率差异无统计学意义（P〉0．05）。结论瑞格列奈联合二甲双胍治疗2型糖尿病，血糖控制良好，并且不增加不良反应。值得临床推广应用。
Objective To investigate the clinical effect of metformin combined with repaglinide in treatment of dia- betes mellitus. Methods 200 patients with type 2 diabetes mellitus in endocrinology department of our hospital from January 2012 to January 2013 were randomly divided into treatment group and control group, with 100 patients in each group. The treatment group was given metformin combined with repaglinide treatment. The control group was only given metformin treatment. Results The postprandial blood glucose 2 h（2 hPG）, fasting blood-glucose （FBG）, glycosy- lated hemoglobin（HbAlc） levels of two groups before treatment were not significantly different（P〉0.05）.Eight weeks af- ter treatment, 2 hPG, FBG, HbAlc levels in the treatment group were significantly lower than that in the control group, the difference was significant （P〈0.05）.The incidence of hypoglycemia, nausea, vomiting, diarrhea of two group compared, the difference was not significant （P〉0.05）. Conclusion The glycemic control effect of metformin combined with repaglin- ide in treatment of type 2 diabetes mellitus is good, and adverse reaction does not increase, worthy of wider applica- tion.
出处
《中国当代医药》
2013年第36期75-76,共2页
China Modern Medicine
关键词
2型糖尿病
二甲双胍
瑞格列奈
Type 2 diabetes mellitus
Metformin
Repaglinide
